SynCore Biotechnology Valuation
| 4192 Stock | TWD 36.30 0.20 0.55% |
At this time, the company appears to be fairly valued. SynCore Biotechnology has a current Real Value of NT$37.06 per share. The regular price of the company is NT$36.3. Our model measures the value of SynCore Biotechnology from inspecting the company fundamentals such as Current Valuation of 2.86 B, return on equity of -0.43, and Shares Owned By Insiders of 66.92 % as well as reviewing its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that SynCore Biotechnology's price fluctuation is very steady at this time. Calculation of the real value of SynCore Biotechnology is based on 3 months time horizon. Increasing SynCore Biotechnology's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the SynCore stock is determined by what a typical buyer is willing to pay for full or partial control of SynCore Biotechnology Co. Since SynCore Biotechnology is currently traded on the exchange, buyers and sellers on that exchange determine the market value of SynCore Stock. However, SynCore Biotechnology's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 36.3 | Real 37.06 | Hype 36.3 | Naive 35.28 |
The intrinsic value of SynCore Biotechnology's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence SynCore Biotechnology's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of SynCore Biotechnology Co helps investors to forecast how SynCore stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of SynCore Biotechnology more accurately as focusing exclusively on SynCore Biotechnology's fundamentals will not take into account other important factors: SynCore Biotechnology Total Value Analysis
SynCore Biotechnology Co is presently anticipated to have takeover price of 2.86 B with market capitalization of 2.88 B, debt of 61.11 M, and cash on hands of 380.81 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the SynCore Biotechnology fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.86 B | 2.88 B | 61.11 M | 380.81 M |
SynCore Biotechnology Investor Information
About 67.0% of the company shares are owned by insiders or employees . The company recorded a loss per share of 3.73. SynCore Biotechnology had not issued any dividends in recent years. The entity had 1000:267 split on the 26th of June 2023. Based on the key measurements obtained from SynCore Biotechnology's financial statements, SynCore Biotechnology Co is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.SynCore Biotechnology Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. SynCore Biotechnology has an asset utilization ratio of 0.84 percent. This indicates that the Company is making NT$0.008417 for each dollar of assets. An increasing asset utilization means that SynCore Biotechnology Co is more efficient with each dollar of assets it utilizes for everyday operations.SynCore Biotechnology Ownership Allocation
SynCore Biotechnology shows a total of 115.08 Million outstanding shares. SynCore Biotechnology has majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 66.92 % of SynCore Biotechnology outstanding shares that are owned by insiders indicates they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.SynCore Biotechnology Profitability Analysis
The company reported the revenue of 6.94 M. Net Loss for the year was (458.6 M) with profit before overhead, payroll, taxes, and interest of 2.97 M.About SynCore Biotechnology Valuation
Our relative valuation model uses a comparative analysis of SynCore Biotechnology. We calculate exposure to SynCore Biotechnology's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of SynCore Biotechnology's related companies.,Ltd, a biopharmaceutical company, engages in the research and development, manufacture, and marketing of drugs in the areas of oncology, ophthalmology, dermatology, and infectious diseases in Taiwan and internationally. The company was founded in 2008 and is headquartered in Yilan, Taiwan. SYNCORE BIOTECHNOL operates under Biotechnology classification in Taiwan and is traded on Taiwan OTC Exchange. It employs 81 people.
8 Steps to conduct SynCore Biotechnology's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates SynCore Biotechnology's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct SynCore Biotechnology's valuation analysis, follow these 8 steps:- Gather financial information: Obtain SynCore Biotechnology's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine SynCore Biotechnology's revenue streams: Identify SynCore Biotechnology's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research SynCore Biotechnology's industry and market trends, including the size of the market, growth rate, and competition.
- Establish SynCore Biotechnology's growth potential: Evaluate SynCore Biotechnology's management, business model, and growth potential.
- Determine SynCore Biotechnology's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate SynCore Biotechnology's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for SynCore Stock Analysis
When running SynCore Biotechnology's price analysis, check to measure SynCore Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy SynCore Biotechnology is operating at the current time. Most of SynCore Biotechnology's value examination focuses on studying past and present price action to predict the probability of SynCore Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move SynCore Biotechnology's price. Additionally, you may evaluate how the addition of SynCore Biotechnology to your portfolios can decrease your overall portfolio volatility.